Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor

The orphan receptor GPR55 is a novel cannabinoid receptor

Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568 · see citing works

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315 · see citing works

G Protein-Coupled Receptor Allosterism and Complexing

Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 934 · see citing works

Agonistic properties of cannabidiol at 5-HT1a receptors

Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878 · see citing works

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands

Pawson, A. J., Sharman, J. L., Benson, H. E., Faccenda, E., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., Southan, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1143 · Cited by 845 · see citing works

Cannabidiol displays unexpectedly high potency as an antagonist of CB 1 and CB 2 receptor agonists in vitro

Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763 · see citing works

Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells

Trettel, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2799 · Cited by 614 · see citing works

The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors

Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 555 · see citing works

Are cannabidiol and Δ9‐tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

McPartland, J. M., Duncan, M., Marzo, V. D., & Pertwee, R. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 526 · see citing works

Cannabidiol—recent advances

Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · see citing works

Emerging paradigms in GPCR allostery: implications for drug discovery

Wootten, D., Christopoulos, A., & Sexton, P. M. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4052 · Cited by 498 · see citing works

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders

Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works

Inverse agonism and neutral antagonism at cannabinoid CB1 receptors

Pertwee, R. G. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.10.025 · Cited by 444 · see citing works

Allosteric Modulation of the Cannabinoid CB1 Receptor

Price, M. R., Baillie, G. L., Thomas, A., Stevenson, L. A., Easson, M., Goodwin, R., Mclean, A., McIntosh, L., Goodwin, G., Walker, G., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016162 · Cited by 418 · see citing works

Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors

Kathmann, M., Flau, K., Redmer, A., Tränkle, C., & Schlicker, E. (2006) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-006-0033-x · Cited by 379 · see citing works

A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer

James, J. R., Oliveira, M. I., Carmo, A. M., Iaboni, A., & Davis, S. J. (2006) · Nature Methods · doi:10.1038/nmeth978 · Cited by 320 · see citing works

Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond

Pertwee, R. G. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00108.x · Cited by 314 · see citing works

Evidence That the Cannabinoid CB1 Receptor Is a 2-Arachidonoylglycerol Receptor

Sugiura, T., Kodaka, T., Nakane, S., Miyashita, T., Kondo, S., Suhara, Y., Takayama, H., Waku, K., Seki, C., Baba, N., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.5.2794 · Cited by 311 · see citing works

Allosteric modulation of G protein-coupled receptors: A pharmacological perspective

Keov, P., Sexton, P. M., & Christopoulos, A. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.010 · Cited by 265 · see citing works

Anti-inflammatory lipoxin A 4 is an endogenous allosteric enhancer of CB 1 cannabinoid receptor

Pamplona, F. A., Ferreira, J., de Lima, O. M., Duarte, F. S., Bento, A. F., Forner, S., Villarinho, J. G., Bellocchio, L., Wotjak, C. T., Lerner, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202906109 · Cited by 178 · see citing works

PSNCBAM‐1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats

Horswill, J. G., Bali, U., Shaban, S. N., Keily, J. F., Jeevaratnam, P., Babbs, A. J., Reynet, C., & In, P. W. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707347 · Cited by 175 · see citing works

(−)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens

Pertwee, R. G., Ross, R. A., Craib, S. J., & Thomas, A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02624-9 · Cited by 156 · see citing works

Type 1 Cannabinoid Receptor Ligands Display Functional Selectivity in a Cell Culture Model of Striatal Medium Spiny Projection Neurons

Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., Dupré, D. J., & Denovan‐Wright, E. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.557025 · Cited by 141 · see citing works

Allosteric Modulator ORG27569 Induces CB1 Cannabinoid Receptor High Affinity Agonist Binding State, Receptor Internalization, and Gi Protein-independent ERK1/2 Kinase Activation

Ahn, K. H., Mahmoud, M. M., & Kendall, D. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316463 · Cited by 141 · see citing works

Distinct Roles of β-Arrestin 1 and β-Arrestin 2 in ORG27569-induced Biased Signaling and Internalization of the Cannabinoid Receptor 1 (CB1)

Ahn, K. H., Mahmoud, M. M., Shim, J., & Kendall, D. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438804 · Cited by 136 · see citing works

Cannabidiol potentiates pharmacological effects of Δ9-tetrahydrocannabinol via CB1 receptor-dependent mechanism

Hayakawa, K., Mishima, K., Hazekawa, M., Sano, K., Irie, K., Orito, K., Egawa, T., Kitamura, Y., Uchida, N., Nishimura, R., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.090 · Cited by 134 · see citing works

CB1 Receptor Allosteric Modulators Display Both Agonist and Signaling Pathway Specificity

Baillie, G. L., Horswill, J. G., Anavi‐Goffer, S., Reggio, P. H., Bolognini, D., Abood, M. E., McAllister, S. D., Strange, P. G., Stephens, G. J., Pertwee, R. G., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.080879 · Cited by 113 · see citing works

Real‐time characterization of cannabinoid receptor 1 ( CB 1) allosteric modulators reveals novel mechanism of action

Cawston, E. E., Redmond, W. J., Breen, C. M., Grimsey, N. L., Connor, M. A., & Glass, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12329 · Cited by 110 · see citing works

Allosterism and cannabinoid CB1 receptors: the shape of things to come

ROSS, R. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.006 · Cited by 91 · see citing works

Constitutive Activity of the Cannabinoid CB1 Receptor Regulates the Function of Co-expressed Mu Opioid Receptors

Canals, M., & Milligan, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710300200 · Cited by 86 · see citing works

Physical and functional interaction between CB1cannabinoid receptors and β2‐adrenoceptors

Hudson, B. D., Hébert, T. E., & Kelly, M. E. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00681.x · Cited by 83 · see citing works

Extracellular Loop 2 of the Free Fatty Acid Receptor 2 Mediates Allosterism of a Phenylacetamide Ago-Allosteric Modulator

Smith, N. J., Ward, R. J., Stoddart, L. A., Hudson, B. D., Kostenis, E., Ulven, T., Morris, J. C., Tränkle, C., Tikhonova, I. G., Adams, D. R., et al. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070789 · Cited by 80 · see citing works

Unbiased Gene Expression Analysis Implicates the huntingtin Polyglutamine Tract in Extra-mitochondrial Energy Metabolism

Lee, J., Ivanova, E. V., Seong, I. S., Cashorali, T., Kohane, I. S., Gusella, J. F., & MacDonald, M. E. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030135 · Cited by 74 · see citing works

Complex Pharmacology of Novel Allosteric Free Fatty Acid 3 Receptor Ligands

Hudson, B. D., Christiansen, E., Murdoch, H., Jenkins, L., Hansen, A. H., Madsen, O., Ulven, T., & Milligan, G. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093294 · Cited by 69 · see citing works

In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569

Gamage, T. F., Ignatowska-Jankowska, B. M., Wiley, J. L., Abdelrahman, M., Trembleau, L., Greig, I. R., Thakur, G. A., Tichkule, R. B., Poklis, J. L., Ross, R. A., et al. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000027 · Cited by 63 · see citing works

Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 Receptor

Piscitelli, F., Ligresti, A., Regina, G. L., Coluccia, A., Morera, L., Allarà, M., Novellino, E., Marzo, V. D., & Silvestri, R. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201485c · Cited by 63 · see citing works

The Membrane Proximal Region of the Cannabinoid Receptor CB1 N-Terminus Can Allosterically Modulate Ligand Affinity

Fay, J. F., & Farrens, D. (2013) · Biochemistry · doi:10.1021/bi400842k · Cited by 47 · see citing works

Presynaptic CB1 cannabinoid receptors control frontocortical serotonin and glutamate release – Species differences

Ferreira, S. G., Teixeira, F. M., Garção, P., Agostinho, P. M., Ledent, C. A., Cortes, L., Mackie, K., & Köfalvi, A. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.05.009 · Cited by 43 · see citing works

Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease

Laprairie, R. B., Kelly, M. E. M., & Denovan‐Wright, E. M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.006 · Cited by 43 · see citing works

Effects of the Allosteric Antagonist 1-(4-Chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 Receptor Modulation in the Cerebellum

Wang, X., Horswill, J. G., Whalley, B. J., & Stephens, G. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.068197 · Cited by 39 · see citing works

Co-expression of the human cannabinoid receptor coding region splice variants (hCB1) affects the function of hCB1 receptor complexes

Bagher, A. M., Laprairie, R. B., Kelly, M. E. M., & Denovan‐Wright, E. M. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.002 · Cited by 37 · see citing works

Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue

Ryan, D., Drysdale, A. J., Pertwee, R. G., & Platt, B. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05448.x · Cited by 35 · see citing works

Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist

Wiley, J. L., Breivogel, C. S., Mahadevan, A., Pertwee, R. G., Cascio, M. G., Bolognini, D., Huffman, J. W., Walentiny, D. M., Vann, R. E., Razdan, R. K., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.085 · Cited by 32 · see citing works

The Cannabinoid 1–Receptor Silent Antagonist O-2050 Attenuates Preference for High-Fat Diet and Activated Astrocytes in Mice

Higuchi, S., Irie, K., Mishima, S., Araki, M., Ohji, M., Shirakawa, A., Akitake, Y., Matsuyama, K., Mishima, K., Mishima, K., et al. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09326sc · Cited by 23 · see citing works

The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients

Laprairie, R. B., Warford, J. R., Hutchings, S., Robertson, G. S., Kelly, M. E. M., & Denovan‐Wright, E. M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.12.008 · Cited by 18 · see citing works

The complex effects of cannabinoids on insulin secretion from rat isolated islets of Langerhans

Anderson, R. L., Randall, M. D., & Chan, S. L. F. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.034 · Cited by 17 · see citing works

Structural analogs of pyrazole and sulfonamide cannabinoids: Effects on acute food intake in mice

Wiley, J. L., Marusich, J. A., Zhang, Y., Fulp, A. B., Maitra, R., Thomas, B. F., & Mahadevan, A. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.08.019 · Cited by 13 · see citing works

Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System

Zou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,362 · see citing works

Phytocannabinoids: a unified critical inventory

Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016) · Natural Product Reports · doi:10.1039/c6np00074f · Cited by 844 · see citing works

Antioxidative and Anti-Inflammatory Properties of Cannabidiol

Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 839 · see citing works

The pharmacokinetics and the pharmacodynamics of cannabinoids

Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724 · see citing works

Practical considerations in medical cannabis administration and dosing

MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663 · see citing works

Cannabidiol: State of the art and new challenges for therapeutic applications

Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M., Fiore, D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.041 · Cited by 625 · see citing works

Cannabinoid Ligands Targeting TRP Channels

Muller, C., Morales, P., & Reggio, P. H. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00487 · Cited by 573 · see citing works

Review of the Endocannabinoid System

Lu, H., & Mackie, K. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.016 · Cited by 511 · see citing works

Molecular Targets of the Phytocannabinoids: A Complex Picture

Morales, P., Hurst, D. P., & Reggio, P. H. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_4 · Cited by 488 · see citing works

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology

Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 482 · see citing works

New approaches and challenges to targeting the endocannabinoid system

Marzo, V. D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.115 · Cited by 480 · see citing works

Cannabidiol Adverse Effects and Toxicity

Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 479 · see citing works

Cannabinoids and Pain: New Insights From Old Molecules

Vuckovic, S. M., Srebro, D., Vujović, K. S., Vučetić, Č., & Prostran, M. S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01259 · Cited by 417 · see citing works

Phytocannabinoids: Origins and Biosynthesis

Gülck, T., & Møller, B. L. (2020) · Trends in Plant Science · doi:10.1016/j.tplants.2020.05.005 · Cited by 393 · see citing works

Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads

Russo, E. B., & Marcu, J. P. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.03.004 · Cited by 379 · see citing works

Changes in delta‐9‐tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta‐analysis

Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M. A., Forti, M. D., & Lynskey, M. T. (2020) · Addiction · doi:10.1111/add.15253 · Cited by 340 · see citing works

Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors

Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan‐Wright, E. M., & Laprairie, R. B. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14440 · Cited by 321 · see citing works

Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials

Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., Freeman, T. P., & McGuire, P. K. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0667-2 · Cited by 317 · see citing works

Cannabidiol: pharmacology and therapeutic targets

Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307 · see citing works

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306 · see citing works

Cannabinoid Delivery Systems for Pain and Inflammation Treatment

Bruni, N., Pepa, C. D., Oliaro‐Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F. (2018) · Molecules · doi:10.3390/molecules23102478 · Cited by 305 · see citing works

Immune Responses Regulated by Cannabidiol

Nichols, J. M., & Kaplan, B. L. F. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 297 · see citing works

A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)

Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 291 · see citing works

Diversity of molecular targets and signaling pathways for CBD

de Almeida, D. L., & Devi, L. A. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.682 · Cited by 264 · see citing works

Cannabis use during pregnancy: Pharmacokinetics and effects on child development

Grant, K. S., Petroff, R., Isoherranen, N., Stella, N., & Burbacher, T. M. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.014 · Cited by 253 · see citing works

The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors

Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.022 · Cited by 246 · see citing works

Molecular Pharmacology of Phytocannabinoids

Turner, S. E., Williams, C. M., Iversen, L. L., & Whalley, B. J. (2017) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-45541-9_3 · Cited by 246 · see citing works

The neuropsychopharmacology of cannabis: A review of human imaging studies

Bloomfield, M., Hindocha, C., Green, S. F., Wall, M. B., Lees, R., Petrilli, K., Costello, H., Ogunbiyi, O., Bossong, M. G., & Freeman, T. P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.006 · Cited by 238 · see citing works

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol

Boggs, D. L., Nguyen, J. D., Morgenson, D., Taffe, M. A., & Ranganathan, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.209 · Cited by 236 · see citing works

Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC

Hložek, T., Uttl, L., Kadeřábek, L., Balı́ková, M., Lhotková, E., Horsley, R. R., Nováková, P., Šíchová, K., Štefková, K., Tylš, F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.10.037 · Cited by 235 · see citing works

Cannabinoids and Cannabinoid Receptors: The Story so Far

Shahbazi, F., Grandi, V., Banerjee, A., & Trant, J. F. (2020) · iScience · doi:10.1016/j.isci.2020.101301 · Cited by 234 · see citing works

The endocannabinoid system as a target for novel anxiolytic drugs

Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233 · see citing works

How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review

Freeman, A. M., Petrilli, K., Lees, R., Hindocha, C., Mokrysz, C., Curran, H. V., Saunders, R., & Freeman, T. P. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.036 · Cited by 222 · see citing works

Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials

Fisher, E., Moore, A., Fogarty, A. E. C., Finn, D. P., Finnerup, N. B., Gilron, I., Haroutounian, S., Krane, E. J., Rice, A. S. C., Rowbotham, M. C., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000001929 · Cited by 219 · see citing works

An overview of the cannabinoid type 2 receptor system and its therapeutic potential

Bie, B., Wu, J., Foss, J. F., & Naguib, M. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000616 · Cited by 208 · see citing works

Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial

Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30290-x · Cited by 202 · see citing works

Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors

Martínez‐Pinilla, E., Varani, K., Reyes‐Resina, I., Angelats, E., Vincenzi, F., Ferreiro‐Vera, C., Oyarzábal, J., Canela, E. I., Lanciego, J. L., Nadal, X., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00744 · Cited by 200 · see citing works

Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination

Gonçalves, J., Rosado, T., Soares, S., Simão, A. Y., Caramelo, D., Luís, Â., Fernández, N., Barroso, M., Gallardo, E., & Duarte, A. P. (2019) · Medicines · doi:10.3390/medicines6010031 · Cited by 192 · see citing works

Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products

An, D., Peigneur, S., Hendrickx, L. A., & Tytgat, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145064 · Cited by 192 · see citing works

Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis

Pamplona, F. A., da Silva, L. R., & Coan, A. C. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00759 · Cited by 190 · see citing works

The Trouble with CBD Oil

Hazekamp, A. (2018) · Medical Cannabis and Cannabinoids · doi:10.1159/000489287 · Cited by 190 · see citing works

Cannabidiol and Other Non-Psychoactive Cannabinoids for Prevention and Treatment of Gastrointestinal Disorders: Useful Nutraceuticals?

Martı́nez, V., Iriondo‐DeHond, A., Borrelli, F., Capasso, R., del Castillo, M. D., & Abalo, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093067 · Cited by 188 · see citing works

Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years

Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183 · see citing works

Anti-rheumatoid drugs advancements: New insights into the molecular treatment of rheumatoid arthritis

Mrid, R. B., Bouchmaa, N., Ainani, H., Fatimy, R. E., Malka, G., & Mazini, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113126 · Cited by 183 · see citing works

Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.

Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181 · see citing works

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol

Morales, P., Reggio, P. H., & Jagerovic, N. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00422 · Cited by 181 · see citing works

In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa

Zagzoog, A., Mohamed, K. A., Kim, H. J. J., Kim, E. D., Frank, C., Black, T., Jadhav, P. D., Holbrook, L. A., & Laprairie, R. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-77175-y · Cited by 180 · see citing works

A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects

Solowij, N., Broyd, S. J., Greenwood, L., van Hell, H., Martelozzo, D., Rueb, K., Todd, J., Liu, Z., Galettis, P., Martin, J. H., et al. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00978-2 · Cited by 176 · see citing works

Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders

Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works

Beyond THC and Endocannabinoids

Pacher, P., Kogan, N. M., & Mechoulam, R. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021441 · Cited by 175 · see citing works

Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy

Franco, V., & Perucca, E. (2019) · Drugs · doi:10.1007/s40265-019-01171-4 · Cited by 171 · see citing works

Cannabidiol (CBD) use in psychiatric disorders: A systematic review

Bonaccorso, S., Ricciardi, A., Zangani, C., Chiappini, S., & Schifano, F. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.08.002 · Cited by 170 · see citing works

Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials

Larsen, C., & Shahinas, J. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4090 · Cited by 170 · see citing works

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169 · see citing works

G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders

Wong, T., Li, G., Li, S., Gao, W., Chen, G., Gan, S., Zhang, M., Li, H., Wu, S., & Du, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01427-2 · Cited by 168 · see citing works

GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol

Laun, A. S., Shrader, S. H., Brown, K. J., & Song, Z.-H. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0031-9 · Cited by 165 · see citing works

The Polypharmacological Effects of Cannabidiol

Castillo-Arellano, J. I., Canseco-Alba, A., Cutler, S. J., & León, F. (2023) · Molecules · doi:10.3390/molecules28073271 · Cited by 163 · see citing works

Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1–CB2 Heteroreceptor Complexes

Navarro, G., Varani, K., Reyes‐Resina, I., de Medina, V. S., Rivas‐Santisteban, R., Callado, C. S.-C., Vincenzi, F., Casano, S., Ferreiro‐Vera, C., Canela, E. I., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00632 · Cited by 161 · see citing works

Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?

Peres, F. F., Lima, A. C., Hallak, J. E. C., Crippa, J. A. S., Silva, R. H., & Abílio, V. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00482 · Cited by 160 · see citing works

Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts

Wold, E. A., Chen, J., Cunningham, K. A., & Zhou, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00875 · Cited by 158 · see citing works

The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease

Kicman, A., & Toczek, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186740 · Cited by 154 · see citing works

Cannabidiol protects an in vitro model of the blood–brain barrier from oxygen‐glucose deprivation via PPARγ and 5‐HT1A receptors

Hind, W. H., England, T. J., & O’Sullivan, S. E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13368 · Cited by 152 · see citing works

Cannabidiol reduces ethanol consumption, motivation and relapse in mice

Viudez‐Martínez, A., García‐Gutiérrez, M. S., Navarrón, C. M., Morales‐Calero, M. I., Navarrete, F., Torres‐Suárez, A. I., & Manzanares, J. (2017) · Addiction Biology · doi:10.1111/adb.12495 · Cited by 152 · see citing works

THC and CBD: Similarities and differences between siblings

Stella, N. (2023) · Neuron · doi:10.1016/j.neuron.2022.12.022 · Cited by 149 · see citing works

Cannabidiol—from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer

Kis, B., Ifrim, F. C., Buda, V. O., Avram, Ș., Pavel, I. Z., Antal, D., Păunescu, V., Dehelean, C. A., Ardelean, F., Diaconeasa, Z. M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235905 · Cited by 148 · see citing works

Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products

Anderson, G. D., & Chan, L. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0400-9 · Cited by 141 · see citing works

Cannabis sativa L. Bioactive Compounds and Their Protective Role in Oxidative Stress and Inflammation

Kopustinskienė, D. M., Masteiková, R., Lažauskas, R., & Bernatonienė, J. (2022) · Antioxidants · doi:10.3390/antiox11040660 · Cited by 141 · see citing works

New Insights in Cannabinoid Receptor Structure and Signaling

Ye, L., Cao, Z., Wang, W., & Zhou, N. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666190215112036 · Cited by 137 · see citing works

Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence

Slivicki, R. A., Xu, Z., Kulkarni, P. M., Pertwee, R. G., Mackie, K., Thakur, G. A., & Hohmann, A. G. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.032 · Cited by 136 · see citing works

The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence

Boyaji, S., Merkow, J. S., Elman, R. N. M., Kaye, A. D., Yong, R. J., & Urman, R. D. (2020) · Current Pain and Headache Reports · doi:10.1007/s11916-020-0835-4 · Cited by 136 · see citing works

Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol

Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135 · see citing works

The Endocannabinoid Signaling System in the CNS

Hillard, C. J. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.10.001 · Cited by 135 · see citing works

Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages

Anil, S. M., Shalev, N., Vinayaka, A. C., Nadarajan, S., Namdar, D., Belausov, E., Shoval, I., Mani, K. A., Mechrez, G., & Koltai, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-81049-2 · Cited by 135 · see citing works

Cannabinoids, Blood–Brain Barrier, and Brain Disposition

Calapai, F., Cardia, L., Sorbara, E. E., Navarra, M., Gangemi, S., Calapai, G., & Mannucci, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030265 · Cited by 131 · see citing works

Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial

Solowij, N., Broyd, S. J., Beale, C., Prick, J.-A., Greenwood, L., van Hell, H., Suo, C., Galettis, P., Pai, N. B., Fu, S., et al. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0043 · Cited by 130 · see citing works

Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus

Luján, M. Á., Castro‐Zavala, A., Alegre-Zurano, L., & Valverde, O. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.043 · Cited by 130 · see citing works

Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

Patricio, F., Morales-Andrade, A. A., Patricio-Martínez, A., & Limón, I. D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595635 · Cited by 129 · see citing works

Cannabis for Chronic Pain: Challenges and Considerations

Romero-Sandoval, E. A., Fincham, J. E., Kolano, A. L., Sharpe, B. N., & Alvarado-Vazquez, P. A. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2115 · Cited by 128 · see citing works

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

Chye, Y., Christensen, E., Solowij, N., & Yücel, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00063 · Cited by 128 · see citing works

Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions

Spanagel, R. (2020) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2020.22.3/rspanagel · Cited by 127 · see citing works

The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?

Moreno, E., Cavic, M. R., Krivokuća, A., Casadó, V., & Canela, E. I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00339 · Cited by 126 · see citing works

Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP)

Klein, B. D., Jacobson, C. A., Metcalf, C. S., Smith, M. D., Wilcox, K. S., Hampson, A. J., & Kehne, J. H. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2287-8 · Cited by 125 · see citing works

Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity

LaVigne, J. E., Hecksel, R., Keresztes, A. I., & Streicher, J. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-87740-8 · Cited by 125 · see citing works

Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment

Premoli, M., Aria, F., Bonini, S. A., Maccarinelli, G., Gianoncelli, A., Pina, S. D., Tambaro, S., Memo, M., & Mastinu, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.053 · Cited by 125 · see citing works

G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits

Azam, S., Haque, M. E., Jakaria, M., Jo, S.-H., Kim, I., & Choi, D. (2020) · Cells · doi:10.3390/cells9020506 · Cited by 124 · see citing works

Chronic Adolescent Δ 9 -Tetrahydrocannabinol Treatment of Male Mice Leads to Long-Term Cognitive and Behavioral Dysfunction, Which Are Prevented by Concurrent Cannabidiol Treatment

Murphy, M. N., Mills, S., Winstone, J., Leishman, E., Wager‐Miller, J., Bradshaw, H. B., & Mackie, K. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0034 · Cited by 122 · see citing works

Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor

Rodríguez-Muñoz, M., Onetti, Y., Cortés‐Montero, E., Garzón, J., & Sánchez‐Blázquez, P. (2018) · Molecular Brain · doi:10.1186/s13041-018-0395-2 · Cited by 122 · see citing works

Beyond Cannabis: Plants and the Endocannabinoid System

Russo, E. B. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.04.005 · Cited by 121 · see citing works

Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation

Pálóczi, J., Varga, Z. V., Hasko, G., & Pacher, P. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7144 · Cited by 121 · see citing works

A Guide to Targeting the Endocannabinoid System in Drug Design

Stasiulewicz, A., Znajdek, K., Grudzień, M. K., Pawiński, T., & Sulkowska, J. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082778 · Cited by 121 · see citing works

Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs

Vaughn, D. M., Kulpa, J., & Paulionis, L. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.00051 · Cited by 119 · see citing works

The potential of cannabidiol in the COVID‐19 pandemic

Esposito, G., Pesce, M., Seguella, L., Sanseverino, W., Lu, J., Corpetti, C., & Sarnelli, G. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15157 · Cited by 118 · see citing works

Clinical management of cannabis withdrawal

Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021) · Addiction · doi:10.1111/add.15743 · Cited by 118 · see citing works

Promising Nanocarriers to Enhance Solubility and Bioavailability of Cannabidiol for a Plethora of Therapeutic Opportunities

Grifoni, L., Vanti, G., Donato, R., Sacco, C., & Bilia, A. R. (2022) · Molecules · doi:10.3390/molecules27186070 · Cited by 118 · see citing works

Cannabis Inflorescence for Medical Purposes: USP Considerations for Quality Attributes

Sarma, N. D., Waye, A., ElSohly, M. A., Brown, P. N., Elzinga, S., Johnson, H. E., Marles, R. J., Melanson, J. E., Russo, E. B., Deyton, L., et al. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.9b01200 · Cited by 117 · see citing works

Cannabis and Cannabinoids for Chronic Pain

Romero-Sandoval, E. A., Kolano, A. L., & Alvarado-Vazquez, P. A. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0693-1 · Cited by 115 · see citing works

Cannabidiol as a potential treatment for psychosis

Davies, C., & Bhattacharyya, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319881916 · Cited by 113 · see citing works

Absence of Entourage: Terpenoids Commonly Found in <i>Cannabis sativa</i> Do Not Modulate the Functional Activity of Δ ⁹ -THC at Human CB ₁ and CB ₂ Receptors

Santiago, M., Sachdev, S., Arnold, J. C., McGregor, I. S., & Connor, M. (2019) · Cannabis &amp; Cannabinoid Research · doi:10.1089/can.2019.0016 · Cited by 112 · see citing works

Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms

Galaj, E., Bi, G., Yang, H.-J., & Xi, Z. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107740 · Cited by 112 · see citing works

Cannabidiol modulates excitatory-inhibitory ratio to counter hippocampal hyperactivity

Rosenberg, E. C., Chamberland, S., Bazelot, M., Nebet, E. R., Wang, X., McKenzie, S., Jain, S. S., Greenhill, S., Wilson, M. A., Marley, N., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.01.018 · Cited by 112 · see citing works

Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study

Chung, H., Fierro, A., & Pessoa-Mahana, C. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220025 · Cited by 75 · see citing works

Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol‐dimethylheptyl at the type 1 and type 2 cannabinoid receptors

Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan‐Wright, E. M., & Laprairie, R. B. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14440 · Cited by 321 · see citing works

Assessing Allosteric Modulation of CB1 at the Receptor and Cellular Levels

Scott, C. E., & Kendall, D. A. (2017) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2017.05.002 · Cited by 9 · see citing works

Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor

Nguyen, T., Li, J., Thomas, B. F., Wiley, J. L., Kenakin, T., & Zhang, Y. (2016) · Medicinal Research Reviews · doi:10.1002/med.21418 · Cited by 95 · see citing works

Pyrimidinyl Biphenylureas Act as Allosteric Modulators to Activate Cannabinoid Receptor 1 and Initiate β-Arrestin–Dependent Responses

Jagla, C. A. D., Scott, C. E., Tang, Y., Qiao, C.-J., Mateo‐Semidey, G. E., Yudowski, G. A., Lu, D., & Kendall, D. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112854 · Cited by 14 · see citing works